Details for New Drug Application (NDA): 018538
✉ Email this page to a colleague
The generic ingredient in LOZOL is indapamide. There are seven drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the indapamide profile page.
Summary for 018538
Tradename: | LOZOL |
Applicant: | Sanofi Aventis Us |
Ingredient: | indapamide |
Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 018538
Profile for product number 001
Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 2.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
Approval Date: | Jul 6, 1983 | TE: | RLD: | Yes |
Profile for product number 002
Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 1.25MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
Approval Date: | Apr 29, 1993 | TE: | RLD: | Yes |
Expired US Patents for NDA 018538
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Sanofi Aventis Us | LOZOL | indapamide | TABLET;ORAL | 018538-001 | Jul 6, 1983 | 3,565,911 | ⤷ Subscribe |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription